Item 8.01 Other Events.

On January 19, 2022, Terns Pharmaceuticals, Inc. (the "Company") announced that Senthil Sundaram, the Company's chief executive officer, has been diagnosed with cancer and will undergo aggressive treatment, including chemotherapy. Mr. Sundaram plans to continue in his role as chief executive officer during his treatment period and to work closely with the Company's board of directors and management team to execute on the Company's business priorities. It is expected that Mr. Sundaram will limit certain business activities, including travel, during his treatment.

The Company requests that Mr. Sundaram's privacy be respected during this period.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses